๐ต๐ฝโ๐ต๐ต ๐ฑ๐ฎ๐ต๐น ๐ฝ๐ฑ๐ฎ ๐ต๐พ๐ฌ๐ด ๐ผ๐ฝ๐ฒ๐ฌ๐ด
1 Followers
On todayโs #BiotechHangout, cover #ASCO24 highlights, shifting pharma oncology interests, more data: $LLY, $AGIO, $ANNX, $AMGN, plus competitive dynamics: $GPCR vs the big leagues, $BBIO / Show more
This is the chart we were referring to: the blue line is over the past year, the red is the previous 17 years.
Striking down Chevron is a much needed brake on the expansion of our administrative State. Good analysis below (from the left) of the background and impact. A very very big deal if you believe government is too big and has too much un-legislative power.
pricing a PIPE at an 18.5% discount to Fridayโs close ($17 vs. $20.86) despite a strong data update recently At that point, why not just take the market risk and do a public offering? Specialists increasingly obscuring natural price discovery